Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes

Diabetes

Volumn 60, Issue 10, 2011, Pages 2617-2623

  Morgantini, Cecilia ^a,b   Natali, Andrea ^a   Boldrini, Beatrice ^a   Imaizumi, Satoshi ^b   Navab, Mohamad ^b   Fogelman, Alan M ^b   Ferrannini, Ele ^a   Reddy, Srinivasa T ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; L 4F PEPTIDE; LOW DENSITY LIPOPROTEIN; PEPTIDOMIMETIC AGENT; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENDOTHELIUM CELL; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; TANDEM MASS SPECTROMETRY;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CASE-CONTROL STUDIES; CELL-FREE SYSTEM; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PEPTIDES; SERUM AMYLOID A PROTEIN;

EID: 80053431876     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0378     Document Type: Article

References (29)

1. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet 1997;349:1347-1352 (Pubitemid 27197536)
2. Spieker LE, Sudano I, Hürlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002;105: 1399-1402 (Pubitemid 34263266)
3. Lubrano V, Baldi S, Ferrannini E, L'Abbate A, Natali A. Role of thromboxane A2 receptor on the effects of oxidized LDL on microvascular endothelium nitric oxide, endothelin-1, and IL-6 production. Microcirculation 2008;15:543-553
4. Norata GD, Raselli S, Grigore L, et al. Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis 2009; 206:556-562
5. Pettersson C, Fogelstrand L, Rosengren B, et al. Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia. J Intern Med 2008;264:155-165 (Pubitemid 351962571)
6. van Hinsbergh VW, Scheffer M, Havekes L, Kempen HJ. Role of endothelial cells and their products in the modification of low-density lipoproteins. Biochim Biophys Acta 1986;878:49-64 (Pubitemid 16049129)
7. Baldi S, Frascerra S, Ferrannini E, Natali A. LDL resistance to oxidation: effects of lipid phenotype, autologous HDL and alanine. Clin Chim Acta 2007;379:95-100 (Pubitemid 46366976)
8. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-283 (Pubitemid 20151285)
9. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-374 (Pubitemid 44394906)
10. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039-2046
11. van Lenten BJ, Hama SY, De Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-2767
12. Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: the immune system and atherogenesis: lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46:389-403
13. van Lenten BJ, Wagner AC, Jung CL, et al. Anti-inflammatory apoA-Imimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 2008;49:2302-2311
14. Morgantini C, Imaizumi S, Grijalva V, Navab M, Fogelman AM, Reddy ST. ApoA-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a mouse model of diabetes. Diabetes 2010;59:3223-3228
15. van Lenten BJ, Wagner AC, Navab M, et al. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 2007;48:2344-2353 (Pubitemid 350058746)
16. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42:1308-1317 (Pubitemid 32744255)
17. Imaizumi S, Grijalva V, Navab M, et al. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett 2010;4:139-148
18. McMahon M, Grossman J, Skaggs B, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009;60:2428-2437
19. Srinivasan S, Hatley ME, Bolick DT, et al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 2004;47:1727-1734 (Pubitemid 40022408)
20. Asleh R, Miller-Lotan R, Aviram M, et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res 2006;99:1419-1425 (Pubitemid 44949678)
21. Unterwurzacher I, Koal T, Bonn GK, Weinberger KM, Ramsay SL. Rapid sample preparation and simultaneous quantitation of prostaglandins and lipoxygenase derived fatty acid metabolites by liquid chromatographymass spectrometry from small sample volumes. Clin Chem Lab Med 2008; 46:1589-1597
22. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-756 (Pubitemid 46348533)
23. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008;49:1344-1352
24. Watson CE, Weissbach N, Kjems L, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 2011;52:361-373
25. Navab M, Reddy ST, Anantharamaiah GM, et al. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res 2011;52:1200-1210
26. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-2756 (Pubitemid 37498976)
27. Navab M, Ananthramaiah GM, Reddy ST, et al. The double jeopardy of HDL. Ann Med 2005;37:173-178 (Pubitemid 40780434)
28. Shao B, Heinecke JW. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. J Proteomics 2011; [Epub ahead of print].
29. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, Hazen SL. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 2009;284:30825-0835